Skip to main content

Hcc

6
Pipeline Programs
13
Companies
11
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Monoclonal Antibody
150%
+ 9 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Eucure Biopharma
Eucure BiopharmaChina - Beijing
1 program
1
YH001 + ToripalimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05212922Withdrawn0Est. Mar 2025
Geneos Therapeutics
Geneos TherapeuticsPA - Philadelphia
1 program
1
GNOS-PV02Phase 1/21 trial
Active Trials
NCT04251117Active Not Recruiting36Est. Nov 2028
CARsgen Therapeutics
CARsgen TherapeuticsChina - Shanghai
1 program
1
CT011 CAR-GPC3 T Cells InjectionPhase 11 trial
Active Trials
NCT06560827Recruiting30Est. Jun 2027
OriCell Therapeutics
OriCell TherapeuticsChina - Shanghai
1 program
1
OriC902Phase 11 trial
Active Trials
NCT06891742Recruiting44Est. Mar 2028
RayzeBio
RayzeBioCA - San Diego
1 program
1
RYZ811Phase 11 trial
Active Trials
NCT06726161Recruiting590Est. Jun 2031
SCG Cell Therapy
SCG Cell TherapySingapore - Singapore
1 program
1
SCG101Phase 11 trial
Active Trials
NCT06617000Recruiting38Est. Dec 2025
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
131I-aGPC3N/A1 trial
Active Trials
NCT07353333Not Yet Recruiting6Est. Dec 2026
Philips
PhilipsNetherlands - Amsterdam
1 program
Double Low-Dose protocol CTN/A1 trial
Active Trials
NCT03045445Completed68Est. Sep 2019
Medtronic
MedtronicNJ - Phillipsburg
1 program
Quirem Medical Holmium-166 radioembolization microspheresN/A1 trial
Active Trials
NCT03437382Completed20Est. Mar 2021
Autonomous Therapeutics
1 program
RFA + SorafenibN/ASmall Molecule1 trial
Active Trials
NCT01470495Unknown430Est. Dec 2018
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
TACEPHASE_21 trial
Active Trials
NCT03817736Completed33Est. Jul 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Eucure BiopharmaYH001 + Toripalimab
Merck & Co.TACE
RayzeBioRYZ811
Geneos TherapeuticsGNOS-PV02
OriCell TherapeuticsOriC902
CARsgen TherapeuticsCT011 CAR-GPC3 T Cells Injection
SCG Cell TherapySCG101
UNION therapeutics131I-aGPC3
MedtronicQuirem Medical Holmium-166 radioembolization microspheres
PhilipsDouble Low-Dose protocol CT
Autonomous TherapeuticsRFA + Sorafenib

Clinical Trials (11)

Total enrollment: 1,295 patients across 11 trials

NCT05212922Eucure BiopharmaYH001 + Toripalimab

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

Start: Jun 2023Est. completion: Mar 20250
Phase 2Withdrawn
NCT03817736Merck & Co.TACE

Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy

Start: Mar 2019Est. completion: Jul 202333 patients
Phase 2Completed
NCT06726161RayzeBioRYZ811

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Start: Sep 2025Est. completion: Jun 2031590 patients
Phase 1/2Recruiting
NCT04251117Geneos TherapeuticsGNOS-PV02

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

Start: Mar 2020Est. completion: Nov 202836 patients
Phase 1/2Active Not Recruiting
NCT06891742OriCell TherapeuticsOriC902

Phase I Study of OriC902 in Treatment of Advanced HCC

Start: Feb 2025Est. completion: Mar 202844 patients
Phase 1Recruiting
NCT06560827CARsgen TherapeuticsCT011 CAR-GPC3 T Cells Injection

CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection

Start: Oct 2023Est. completion: Jun 202730 patients
Phase 1Recruiting
NCT06617000SCG Cell TherapySCG101

A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

Start: Oct 2022Est. completion: Dec 202538 patients
Phase 1Recruiting
NCT07353333UNION therapeutics131I-aGPC3

Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3

Start: Jan 2026Est. completion: Dec 20266 patients
N/ANot Yet Recruiting
NCT03437382MedtronicQuirem Medical Holmium-166 radioembolization microspheres

Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study

Start: Jul 2018Est. completion: Mar 202120 patients
N/ACompleted
NCT03045445PhilipsDouble Low-Dose protocol CT

"Double Low-Dose" DECT for HCC Imaging

Start: May 2017Est. completion: Sep 201968 patients
N/ACompleted
NCT01470495Autonomous TherapeuticsRFA + Sorafenib

Combined Treatment of RFA and Sorafenib on Recurrent HCC

Start: Jan 2015Est. completion: Dec 2018430 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 1,295 patients
13 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.